Content
@
0 reply
0 recast
0 reaction
duytdcrypto
@duytd1
A study from Washington University School of Medicine suggests that the experimental drug gantenerumab may help delay cognitive decline in people at genetic risk for early Alzheimer’s. The results, published in The Lancet Neurology, found that those who took the drug for the longest period (an average of eight years) reduced their risk of cognitive decline by 50%. Gantenerumab is an antibody that targets beta-amyloid plaques in the brain, helping to break them down and prevent new ones from forming. The drug has previously failed in trials in patients with Alzheimer’s symptoms, but new research suggests that early use may be key to its effectiveness.
0 reply
0 recast
0 reaction
